The proliferation index, assessed using Ki67, is considered an important prognostic biomarker in BC.4 Ki67 is typically useful in ER-positive/HER2-negative BC to discriminate, together with PR, luminal A from luminal B cases, as recommended by St. This evidence concerns the gene PGR and breast cancer.